|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
|
|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||
| Cash and cash equivalent | ||||||||||
| Cash | ||||||||||
| Other receivables (Note 6) | ||||||||||
| Prepaid expenses | ||||||||||
| Total Current Assets | ||||||||||
| Prepaid expenses – non-current | ||||||||||
| Cash held in trust escrow account | ||||||||||
| Investment held in trust account | ||||||||||
| Cash held in escrow account | ||||||||||
| Total Non-Current Assets | ||||||||||
| Total Assets | ||||||||||
| LIABILITIES AND SHAREHOLDERS’ DEFICIT | ||||||||||
| Current liabilities: | ||||||||||
| Accrued expenses | ||||||||||
| Promissory note – extension | ||||||||||
| Related Party | ||||||||||
| Total promissory note – extension | ||||||||||
| Payable to target | ||||||||||
| Due to related party | ||||||||||
| Total Current Liabilities | ||||||||||
| Deferred underwriting commission payable | ||||||||||
| Total Liabilities | ||||||||||
| Ordinary shares subject to possible redemption (881,636 and 1,005,792 shares at redemption value of $12.21 and $11.69 as of June 30, 2026 and December 31, 2025, respectively) | ||||||||||
| Shareholders’ Deficit: | ||||||||||
| Ordinary shares, $0.0001 par value; 200,000,000 shares authorized; 1,732,500 shares issued and outstanding (excluding 881,636 and 1,005,792 shares subject to possible redemption) at June 30, 2026 and December 31, 2025, respectively | ||||||||||
| Accumulated Deficit | ||||||||||
| Total Shareholders’ Deficit | ||||||||||
| Total Liabilities and Shareholders’ Deficit |
Loading...
